PD-1/PD-L1 immunotherapy resistance in NSCLC is described, e.g., as being attributed to the loss-of-function of IFN signaling and the resulting decrease in IFN-γ-induced PD-L1 expression in cancer cells [21]. Here, IFNG is linked to cancer.